A citation-based method for searching scientific literature

Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent.
Sushanta Bhattacharya, Akash Rathore, Deepa Parwani, Chaitali Mallick, Vivek Asati, Shivangi Agarwal, Vaibhav Rajoriya, Ratnesh Das, Sushil Kumar Kashaw. Eur J Med Chem 2020
13
100

Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
David Z Cherney, Ayodele Odutayo, Ronnie Aronson, Justin Ezekowitz, John D Parker. J Am Coll Cardiol 2019
33
50


Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.
Viswanathan Mohan, Ambrish Mithal, Shashank R Joshi, S R Aravind, Subhankar Chowdhury. Drug Des Devel Ther 2020
11
50



Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Xiaoyan Zhang, Maud Urbanski, Mona Patel, Geoffrey G Cox, Roxanne E Zeck, Haiyan Bian, Bruce R Conway, Mary Pat Beavers, Philip J Rybczynski, Keith T Demarest. Bioorg Med Chem Lett 2006
22
50

Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Nobuhiko Fushimi, Hideki Fujikura, Hiroaki Shiohara, Hirotaka Teranishi, Kazuo Shimizu, Shigeru Yonekubo, Kohsuke Ohno, Takashi Miyagi, Fumiaki Itoh, Toshihide Shibazaki,[...]. Bioorg Med Chem 2012
12
50

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, Joanne Saye, Shamik Parikh, James F List. Diabetes Metab Syndr Obes 2012
47
50

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
50

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
R L Dobbins, R O'Connor-Semmes, A Kapur, C Kapitza, G Golor, I Mikoshiba, W Tao, E K Hussey. Diabetes Obes Metab 2012
48
50


Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
61
50

NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities.
Hugo E. Gottlieb, Vadim Kotlyar, Abraham Nudelman. J Org Chem 1997
50

Current anti-diabetic agents and their molecular targets: A review.
Nagaraju Kerru, Ashona Singh-Pillay, Paul Awolade, Parvesh Singh. Eur J Med Chem 2018
127
50

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
50

Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter.
E Turk, B Zabel, S Mundlos, J Dyer, E M Wright. Nature 1991
286
50

Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors.
Koji Ohsumi, Hiroyuki Matsueda, Toshihiro Hatanaka, Ryusuke Hirama, Takashi Umemura, Akiko Oonuki, Nozomu Ishida, Yoko Kageyama, Katsumi Maezono, Nobuo Kondo. Bioorg Med Chem Lett 2003
34
50

Inhibitor binding mode and allosteric regulation of Na+-glucose symporters.
Paola Bisignano, Chiara Ghezzi, Hyunil Jo, Nicholas F Polizzi, Thorsten Althoff, Chakrapani Kalyanaraman, Rosmarie Friemann, Matthew P Jacobson, Ernest M Wright, Michael Grabe. Nat Commun 2018
23
50

Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
556
50

Optimization of pharmacokinetic properties by modification of a carbazole-based cannabinoid receptor subtype 2 (CB2) ligand.
Dominik Heimann, Frederik Börgel, Henk de Vries, Kim Bachmann, Victoria E Rose, Bastian Frehland, Dirk Schepmann, Laura H Heitman, Bernhard Wünsch. Eur J Med Chem 2018
9
50

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
126
50

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
A P Sykes, R O'Connor-Semmes, R Dobbins, D J Dorey, J D Lorimer, S Walker, W O Wilkison, L Kler. Diabetes Obes Metab 2015
21
50

Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice.
Shigeru Nakano, Kenji Katsuno, Masayuki Isaji, Tatsuya Nagasawa, Benjamin Buehrer, Susan Walker, William O Wilkison, Bentley Cheatham. J Clin Exp Hepatol 2015
56
50


Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Elizabeth K Hussey, Anita Kapur, Robin O'Connor-Semmes, Wenli Tao, Bryan Rafferty, Joseph W Polli, Charles D James, Robert L Dobbins. BMC Pharmacol Toxicol 2013
27
50


SGLT2 inhibition--a novel strategy for diabetes treatment.
Edward C Chao, Robert R Henry. Nat Rev Drug Discov 2010
455
50

Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Eur J Med Chem 2019
10
50

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Mala Dharmalingam, S R Aravind, Hemant Thacker, S Paramesh, Brij Mohan, Manoj Chawla, Arthur Asirvatham, Ramesh Goyal, Jayashri Shembalkar, R Balamurugan,[...]. Drugs 2020
14
50

Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4'-dehydroxyphlorizin derivatives.
M Hongu, T Tanaka, N Funami, K Saito, K Arakawa, M Matsumoto, K Tsujihara. Chem Pharm Bull (Tokyo) 1998
22
50

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, Yukiko Ishikawa-Takemura, Hideki Fujikura, Masayuki Isaji. J Pharmacol Exp Ther 2008
152
50

Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Xiaoyan Zhang, Maud Urbanski, Mona Patel, Roxanne E Zeck, Geoffrey G Cox, Haiyan Bian, Bruce R Conway, Mary Pat Beavers, Philip J Rybczynski, Keith T Demarest. Bioorg Med Chem Lett 2005
22
50

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Takayoshi Suga, Osamu Kikuchi, Masaki Kobayashi, Sho Matsui, Hiromi Yokota-Hashimoto, Eri Wada, Daisuke Kohno, Tsutomu Sasaki, Kazusane Takeuchi, Satoru Kakizaki,[...]. Mol Metab 2019
58
50

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
12
50

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
9
50

Genital mycotic infections in patients with diabetes.
Paul Nyirjesy, Jack D Sobel. Postgrad Med 2013
47
50


Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Thomas Danne, Torben Biester, Olga Kordonouri. Diabetes Technol Ther 2018
29
50

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
54
50

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
10
50


Comparison of Quality of Life and Nutritional Status of Between Roux-en-Y and Billroth-I Reconstruction After Distal Gastrectomy: A Systematic Review and Meta-Analysis.
Nannan Du, Manman Chen, Zefeng Shen, Shengnan Li, Ping Chen, Parishit A Khadaroo, Danyi Mao, Lihu Gu. Nutr Cancer 2020
8
50

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Bruce W Bode, Eda Cengiz, R Paul Wadwa, Phillip Banks, Thomas Danne, Jake A Kushner, Darren K McGuire, Anne L Peters, Paul Strumph, Sangeeta Sawhney. Diabetes Technol Ther 2021
4
50

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
6
50

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
95
50

Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
Kristin Engelhardt, McKenzie Ferguson, Jennifer L Rosselli. Ann Pharmacother 2021
13
50

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer,[...]. Mol Metab 2020
20
50

A review of sotagliflozin for use in type 1 diabetes.
Wesley Nuffer, Briana Williams, Jennifer M Trujillo. Ther Adv Endocrinol Metab 2019
7
50

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
Janet B McGill, Savitha Subramanian. Am J Cardiol 2019
31
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.